<DOC>
	<DOCNO>NCT01122134</DOCNO>
	<brief_summary>Intravenous artesunate highly effective rapid schizonticidal action improve clinical outcome</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics Intravenous Artesunate Severe Malaria Treatment</brief_title>
	<detailed_description>The current first line treatment severe malaria Uganda intravenous quinine artemisinin derivative alternative . Intravenous artesunate , water soluble artemisinin derivative effective quinine faster schizonticidal action improve clinical outcome . It generally well tolerate safe . This study aim assess pharmacokinetics , pharmacodynamics safety IV artesunate treatment severe malaria adult admit Mulago National Referral Teaching hospital , Uganda .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>1 . Patients age 18 year 2 . With severe malaria accord follow ciriteria : 3 . A positive blood smear malaria P. falciparum monoinfection parasitemia &gt; 500 parasites/ul blood 4. Who accord attend physician require parenteral treatment admission malaria 5 . Willing participate study 6. Who whose first degree parents/caretakers able provide write informed consent 1 . Patients history prior antimalarial use within last 72 hour 2 . Pregnant woman 3 . Patients contraindication take study drug 4 . Patients take known inhibitor inducer cytochrome P450</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>severe</keyword>
	<keyword>malaria</keyword>
	<keyword>artesunate</keyword>
	<keyword>intravenous</keyword>
</DOC>